Table 5.
Variables related to inflammation at baseline and at the end of the study in patients treated with the DHA supplement and in controls.
| Variables | Control Group (n = 15) | DHA Group (n = 19) | Within-Group p Value |
Between-Group p Value |
||||
|---|---|---|---|---|---|---|---|---|
| Baseline | End of Study | Baseline | End of Study | Control Group | DHA Group | Baseline | End of Study | |
| IL-1β, pg/mL | 5.02 (0.43) | 7.43 (0.66) | 5.21 (0.47) | 6.24 (0.60) | 0.002 | 0.129 | 0.701 | 0.146 |
| IL-4, pg/mL | 2.84 (0.29) | 3.65 (0.34) | 2.89 (0.28) | 2.19 (0.22) | 0.002 | 0.087 | 0.805 | 0.0003 |
| IL-6, pg/mL | 5.18 (0.43) | 5.04 (0.44) | 5.05 (0.37) | 3.17 (0.24) | 0.743 | 0.0002 | 0.714 | 0.001 |
| IL-10, pg/mL | 4.21 (0.37) | 5.66 (0.52) | 4.15 (0.32) | 4.81 (0.54) | 0.015 | 0.404 | 0.939 | 0.167 |
| IL-18, pg/mL | 73.0 (6.09) | 74.97 (6.39) | 80.52 (7.17) | 79.74 (6.57) | 0.745 | 0.999 | 0.522 | 0.652 |
| TNF-α, pg/mL | 39.45 (3.81) | 43.29 (4.07) | 58.53 (5.17) | 49.36 (4.28) | 0.274 | 0.059 | 0.009 | 0.437 |
| VEGF-A, pg/mL | 13.46 (1.28) | 16.72 (1.73) | 15.04 (1.42) | 10.42 (1.90) | 0.231 | 0.011 | 0.528 | 0.020 |
IL: interleukin; TNF: tumor necrosis factor; VEGF: vascular endothelial growth factor. Data expressed as mean and standard error of the mean (SEM).